Patricia A. Kruk

ORCID: 0000-0002-7441-9387 · 6 papers in corpus
lab-animal 2015
BioMed research international ·doi:10.1155/2015/652017

Familial history remains the strongest risk factor for developing ovarian cancer (OC) and is associated with germline BRCA1 mutations, such as the 185delAG founder mutation. We sought to determine whether normal human ovarian surface epithe…

observational 2014
Journal of ovarian research ·doi:10.1186/s13048-014-0104-4

BACKGROUND: Early detection of epithelial ovarian cancer (OC) is necessary to overcome the high mortality rate of late stage diagnosis; and, examining the molecular changes that occur at early disease onset may provide new strategies for OC…

observational 2013

While semaphorins and their receptors appear to play a role in tumor carcinogenesis, little is known about the role of semaphorin 3F (S3F) in epithelial ovarian cancer (EOC) development. Therefore, we sought to determine the clinical relati…

2011
·doi:10.1158/1538-7445.am2011-2226

Abstract Background: Fallopian tube intraepithelial cancer is a potential precursor of high-grade, sporadic and familial, pelvic carcinomas. Materials and Methods: Using a protocol for rapid intraoperative cytology (IC), fallopian tube fimb…

review 2011
Obstetrics and Gynecology International ·doi:10.1155/2011/358493

Ovarian epithelial cancer is the most lethal gynecologic malignancy. The high mortality is attributed to the fact that most cases typically present in late stage when ovarian cancer (OC) has already spread beyond the ovary. Ovarian epitheli…

other 2009
Gynecologic Oncology ·doi:10.1016/j.ygyno.2008.09.037

OBJECTIVE(S): The poor prognosis associated with ovarian cancer is due to the lack of overt early symptoms and the absence of reliable diagnostic screening methods. Since many tumors overexpress anti-apoptotic proteins, the purpose of this …